Prophylactic agent and/or therapeutic agent for sepsis

A technology for sepsis and preventive agents, applied in the field of preventive and/or therapeutic agents for sepsis, which can solve the problems of exacerbation of infectious diseases, unrealistic, and no progress in research, and achieve the goals of reducing side effects, improving drug efficacy, and excellent therapeutic effects Effect

Active Publication Date: 2014-04-23
SBI PHARMA CO LTD +1
View PDF7 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, since the absorption wavelength suitable for PPIX excitation overlaps with the absorption spectrum of hemoglobin, it is necessary to insert the excitation light source into the blood vessel with the help of a catheter, etc., which may promote further infection and worsen the infection. Objection, but also because it is not realistic, so the research has not progressed
In addition, even if PDT can be a bactericidal technique, it is ineffective against the hypercytokineemia mentioned above

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prophylactic agent and/or therapeutic agent for sepsis
  • Prophylactic agent and/or therapeutic agent for sepsis
  • Prophylactic agent and/or therapeutic agent for sepsis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0097] Using a sepsis model in which human pulmonary artery endothelial cells were mixed with lipopolysaccharide (LPS), which can promote the secretion of inflammatory cytokines, the ELISA method was used to measure IL-6 in the supernatant ( figure 1 ), IL-8 ( figure 2 ) for the following experiments. The organ with the highest frequency of damage in sepsis is the lung, so human pulmonary artery endothelial cells were used in this experiment.

[0098] Human pulmonary artery endothelial cells (5×10 5 cells / well, n=3 wells), and were divided into the following 4 groups according to whether LPS and 5-ALA were added.

[0099] (1) Control without stimulation (in the figure: control)

[0100] (2) Add 5-ALA (100μM) and mix for 3 hours (in the figure: +ALA)

[0101](3) Add LPS (1μg / mL) and mix for 3 hours (in the figure: +LPS)

[0102] (4) Add 5-ALA (100μM) and LPS (1μg / mL) and mix for 3 hours (in the figure: +ALA, LPS)

[0103] In the group to which 5-ALA was added, sodium fer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a sepsis treatment drug which is useful in preventing and treating sepsis. A prophylactic agent and / or therapeutic agent for sepsis, the agent containing as an active ingredient 5-aminolevulinic acid (5-ALA), a derivative thereof, or a pharmacologically acceptable salt thereof, is prepared. Preferably, the ALA contains sodium ferrous citrate or another metal-containing compound. Appropriate examples of the ALA include: ALA; methyl, ethyl, propyl, butyl, pentyl, and other esters thereof; hydrochlorides, phosphates, and sulfates thereof; and the like.

Description

technical field [0001] The present invention relates to a preventive and / or therapeutic agent for sepsis, and more specifically, to an agent for sepsis containing 5-aminolevulinic acid (5-ALA) or a derivative thereof or a pharmacologically acceptable salt thereof as an active ingredient Prophylactic and / or therapeutic agents. Background technique [0002] Sepsis has been identified as a highly severe systemic inflammatory response syndrome (systemic inflammatory response syndrome: SIRS) caused by bacterial infections such as trauma, puerperium, and disease. The essence of SIRS is hypercytokineemia. Due to the action of cytokines as inflammatory substances and toxins released by infected bacteria, blood vessels dilate and cause blood pressure to drop. If this drop in blood pressure progresses significantly, the risk of dysfunction of various internal organs increases due to insufficient blood flow to various parts of the body. If the blood flow of the heart is increased to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/197A61K31/28A61K31/295A61K33/06A61K33/26A61K33/30A61K33/34A61P31/04A61P43/00
CPCA61K31/28A61K31/197A61K45/06A61K33/26A61K31/295A61P31/04A61P43/00
Inventor 木下浩作丹正胜久其他发明人请求不公开姓名
Owner SBI PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap